Valuation: Sanofi

Market Cap 85.78B 95.82B 79.97B 72.53B 137B 9,160B 138B 961B 376B 4,727B 360B 352B 15,211B P/E 2026 *
11.6x
P/E 2027 * 10x
Enterprise Value 97.12B 108B 90.53B 82.12B 155B 10,371B 156B 1,088B 426B 5,352B 408B 398B 17,221B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 1.86x
Free-Float
88.34%
Yield 2026 *
5.94%
Yield 2027 * 6.29%
1 week+1.14%
Current month-2.20%
1 month-3.26%
3 months-6.32%
6 months-10.55%
Current year-12.75%
1 week 34.8
Extreme 34.8
36
1 month 34.6
Extreme 34.6
37.6
3 years 34.6
Extreme 34.6
55
5 years 34.6
Extreme 34.6
55
10 years 30.6
Extreme 30.6
55
Manager TitleAgeSince
Chief Executive Officer 65 30/04/2026
Director of Finance/CFO 64 31/03/2024
Chief Tech/Sci/R&D Officer - 31/08/2026
Director TitleAgeSince
Director/Board Member 61 29/04/2019
Director/Board Member 56 27/04/2020
Director/Board Member 65 27/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.56%-15.24%-30.20% 95.94B
+0.28%+3.46%+41.89%+93.71% 1,051B
+0.88%+4.27%+38.28%+68.70% 630B
+1.68%+5.78%+21.96%+89.56% 489B
-0.10%+4.24%+69.15%+40.41% 359B
+0.61%+3.18%+24.05%+42.46% 344B
+0.72%+2.99%+14.29%+34.71% 272B
+0.23%+2.23%-5.91%+8.15% 246B
+0.65%+3.62%+43.93%+46.50% 224B
-0.49%+4.01%+28.38%+95.97% 187B
Average +0.43%+3.11%+26.08%+49.00% 422.63B
Weighted average by Cap. +0.41%+3.18%+32.86%+64.54%

Financials

2026 *2027 *
Net sales 47.35B 52.89B 44.14B 40.03B 75.51B 5,056B 75.98B 530B 208B 2,609B 199B 194B 8,396B 50.47B 56.37B 47.04B 42.67B 80.48B 5,389B 80.99B 565B 221B 2,781B 212B 207B 8,949B
Net income 7.3B 8.15B 6.8B 6.17B 11.64B 779B 11.71B 81.75B 32B 402B 30.62B 29.94B 1,294B 8.81B 9.85B 8.22B 7.45B 14.06B 941B 14.14B 98.74B 38.65B 486B 36.98B 36.16B 1,563B
Net Debt 11.34B 12.66B 10.57B 9.58B 18.08B 1,210B 18.19B 127B 49.71B 625B 47.57B 46.51B 2,010B 8B 8.94B 7.46B 6.77B 12.76B 855B 12.84B 89.66B 35.1B 441B 33.58B 32.84B 1,419B
Projected Income Statement - Annual - Sanofi
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Date Price Change
12/10/26 €35.60 0.00%
09/10/26 €35.60 -0.56%
08/10/26 €35.80 0.00%
07/10/26 €35.80 +2.29%
06/10/26 €35.00 -0.57%
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Sanofi
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
71.60EUR
Average target price
93.56EUR
Spread / Average Target
+30.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sanofi